Patents by Inventor Emily P. Hsu

Emily P. Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190135718
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: August 6, 2018
    Publication date: May 9, 2019
    Inventors: Junying Yuan, Emily P. Hsu
  • Publication number: 20170305824
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: February 8, 2017
    Publication date: October 26, 2017
    Inventors: Junying Yuan, Emily P. Hsu
  • Patent number: 9586880
    Abstract: Compounds having the following structure (VI-A): or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, wherein RE1, RE2, RE3, RE4, ZE2 and ZE3 are as disclosed herein, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating disorders associated with necrosptosis are also provided.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: March 7, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Junying Yuan, Emily P. Hsu